中药治疗胰腺纤维化的新兴作用
本文综述中药在慢性胰腺炎相关胰腺纤维化中的体外与体内研究进展及潜在机制,指出中药多通过TGF-β/Smads通路作用于多个分子靶点,并概述部分中药的毒理学以提示用药安全。
要点
- 中药抗胰腺纤维化机制多涉及TGF-β/Smads通路及多靶点作用。
- 现有临床手段以缓解症状为主,不能治愈胰腺纤维化。
- 综述同时概述部分中药毒理学,提示关注用药安全。
核心结论
- 中药在慢性胰腺炎相关胰腺纤维化的防治中具有研究价值,但需兼顾毒理学与用药安全。
研究设计与样本
- 综述类文章,聚焦中药抗慢性胰腺炎所致胰腺纤维化的体外与体内研究进展。
主要发现
- 中药可作用于胰腺纤维化发病机制中的多个分子靶点,主要涉及TGF-β/Smads通路。
临床怎么用
- 可为中药创新药物研发及慢性胰腺炎伴胰腺纤维化的治疗发展提供参考。
局限性
- 该领域缺乏整合且最新的交流,胰腺纤维化机制尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pancreatic fibrosis is the main pathologic characteristic in chronic pancreatitis (CP), a common disease that arises from surgery. Pancreatitis is caused by various etiologies, but the mechanism of fibrosis is not completely understood. Existing clinical approaches mainly focus on mitigating the symptoms and therefore do not cure the phenomena. In recent years, there has been a heightened interest in the use of Chinese herbal medicine (CHMs) in the prevention and cure of CP as expressed by increasing numbers of clinical and experimental research. Despite early cell culture and animal models, CHMs are able to interact with plenty of molecular targets involved in the pathogenesis of pancreatic fibrosis mostly via the TGF- β /Smads pathway; however, integrated and up-to-date communication in this domain is unavailable. This review focuses on the research progress of CHMs against pancreatic fibrosis due to CP in vitro and in vivo and summarizes the potential mechanisms. We also outlined the toxicology of some CHMs for fibrosis treatment in order to provide a fuller understanding of drug safety. This review may provide reference for further innovative drug research and the future development of treatments for CP with pancreatic fibrosis.
引用
- Liu C, Li S, Zhang Q, et al. Emerging Role of Chinese Herbal Medicines in the Treatment of Pancreatic Fibrosis. Am J Chin Med. 2019. PMID: 31091974. doi:10.1142/S0192415X1950037X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。